Cargando…
Misreporting of contraceptive hormone use in clinical research participants
OBJECTIVE: Researchers traditionally rely on participant self-report for contraceptive use. We hypothesized that self-reported contraceptive use by clinical research participants may disagree with objectively measured hormonal status. STUDY DESIGN: We enrolled women in Harare, Zimbabwe, aged 18–34,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858917/ https://www.ncbi.nlm.nih.gov/pubmed/28966052 http://dx.doi.org/10.1016/j.contraception.2017.09.013 |
_version_ | 1783307725364527104 |
---|---|
author | Achilles, Sharon L. Mhlanga, Felix G. Musara, Petina Poloyac, Samuel M. Chirenje, Zvavahera M. Hillier, Sharon L. |
author_facet | Achilles, Sharon L. Mhlanga, Felix G. Musara, Petina Poloyac, Samuel M. Chirenje, Zvavahera M. Hillier, Sharon L. |
author_sort | Achilles, Sharon L. |
collection | PubMed |
description | OBJECTIVE: Researchers traditionally rely on participant self-report for contraceptive use. We hypothesized that self-reported contraceptive use by clinical research participants may disagree with objectively measured hormonal status. STUDY DESIGN: We enrolled women in Harare, Zimbabwe, aged 18–34, who by self-report had not used hormonal or intrauterine contraception for >30 days, or depot medroxyprogesterone acetate for >10 months, into a study designed to assess biologic changes with contraceptive initiation and use. Blood samples obtained at enrollment and each follow-up visit (N=1630 from 447 participants) were evaluated by mass spectrometry for exogenous hormones. We individually interviewed a subset of participants (n=20) with discrepant self-reported and measured serum hormones to better understand nondisclosure of contraceptive use. RESULTS: Discrepant with self-reported nonuse of hormonal contraception, synthetic progestogens were detectable in 120/447 (27%, 95% confidence interval 23%–31%) enrolled women. Measured exogenous hormones consistent with use of contraceptive pills (n=102), injectables (n=20) and implants (n=3) were detected at enrollment, with 7 women likely using >1 contraceptive. In-depth interviews revealed that participants understood the requirement to be hormone free at enrollment (100%). Most (85%) cited partner noncooperation with condoms/withdrawal and/or pregnancy concerns as major reasons for nondisclosed contraceptive use. All interviewed women (100%) cited access to health care as a primary motivation for study participation. Of participants who accurately reported nonuse of hormonal contraception at enrollment, 41/327 (12.5%) had objective evidence of nonstudy progestin use at follow-up that disagreed with self-reported nonuse. CONCLUSIONS: Women joining contraceptive research studies may misrepresent their use of nonstudy contraceptive hormones at baseline and follow-up. Objective measures of hormone use are needed to ensure that study population exposures are accurately categorized. IMPLICATIONS STATEMENT: Among Zimbabwean women participating in a contraceptive research study, 27% had objective evidence of use of nonstudy contraceptives at enrollment that disagreed with self-report. Studies that rely on self-report to identify contraceptive hormone exposure could suffer from significant misclassification. |
format | Online Article Text |
id | pubmed-5858917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-58589172018-04-01 Misreporting of contraceptive hormone use in clinical research participants Achilles, Sharon L. Mhlanga, Felix G. Musara, Petina Poloyac, Samuel M. Chirenje, Zvavahera M. Hillier, Sharon L. Contraception Article OBJECTIVE: Researchers traditionally rely on participant self-report for contraceptive use. We hypothesized that self-reported contraceptive use by clinical research participants may disagree with objectively measured hormonal status. STUDY DESIGN: We enrolled women in Harare, Zimbabwe, aged 18–34, who by self-report had not used hormonal or intrauterine contraception for >30 days, or depot medroxyprogesterone acetate for >10 months, into a study designed to assess biologic changes with contraceptive initiation and use. Blood samples obtained at enrollment and each follow-up visit (N=1630 from 447 participants) were evaluated by mass spectrometry for exogenous hormones. We individually interviewed a subset of participants (n=20) with discrepant self-reported and measured serum hormones to better understand nondisclosure of contraceptive use. RESULTS: Discrepant with self-reported nonuse of hormonal contraception, synthetic progestogens were detectable in 120/447 (27%, 95% confidence interval 23%–31%) enrolled women. Measured exogenous hormones consistent with use of contraceptive pills (n=102), injectables (n=20) and implants (n=3) were detected at enrollment, with 7 women likely using >1 contraceptive. In-depth interviews revealed that participants understood the requirement to be hormone free at enrollment (100%). Most (85%) cited partner noncooperation with condoms/withdrawal and/or pregnancy concerns as major reasons for nondisclosed contraceptive use. All interviewed women (100%) cited access to health care as a primary motivation for study participation. Of participants who accurately reported nonuse of hormonal contraception at enrollment, 41/327 (12.5%) had objective evidence of nonstudy progestin use at follow-up that disagreed with self-reported nonuse. CONCLUSIONS: Women joining contraceptive research studies may misrepresent their use of nonstudy contraceptive hormones at baseline and follow-up. Objective measures of hormone use are needed to ensure that study population exposures are accurately categorized. IMPLICATIONS STATEMENT: Among Zimbabwean women participating in a contraceptive research study, 27% had objective evidence of use of nonstudy contraceptives at enrollment that disagreed with self-report. Studies that rely on self-report to identify contraceptive hormone exposure could suffer from significant misclassification. Elsevier 2018-04 /pmc/articles/PMC5858917/ /pubmed/28966052 http://dx.doi.org/10.1016/j.contraception.2017.09.013 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Achilles, Sharon L. Mhlanga, Felix G. Musara, Petina Poloyac, Samuel M. Chirenje, Zvavahera M. Hillier, Sharon L. Misreporting of contraceptive hormone use in clinical research participants |
title | Misreporting of contraceptive hormone use in clinical research participants |
title_full | Misreporting of contraceptive hormone use in clinical research participants |
title_fullStr | Misreporting of contraceptive hormone use in clinical research participants |
title_full_unstemmed | Misreporting of contraceptive hormone use in clinical research participants |
title_short | Misreporting of contraceptive hormone use in clinical research participants |
title_sort | misreporting of contraceptive hormone use in clinical research participants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858917/ https://www.ncbi.nlm.nih.gov/pubmed/28966052 http://dx.doi.org/10.1016/j.contraception.2017.09.013 |
work_keys_str_mv | AT achillessharonl misreportingofcontraceptivehormoneuseinclinicalresearchparticipants AT mhlangafelixg misreportingofcontraceptivehormoneuseinclinicalresearchparticipants AT musarapetina misreportingofcontraceptivehormoneuseinclinicalresearchparticipants AT poloyacsamuelm misreportingofcontraceptivehormoneuseinclinicalresearchparticipants AT chirenjezvavaheram misreportingofcontraceptivehormoneuseinclinicalresearchparticipants AT hilliersharonl misreportingofcontraceptivehormoneuseinclinicalresearchparticipants |